PPARγ and MEK Interactions in Cancer
2008
Interactions of PPARγ and MEK in Cancer
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Elke Burgermeister, Rony Seger
Hypothesis
How do PPARγ and its ligands interact with the MEK-ERK signaling pathway in cancer?
Conclusion
PPARγ can act as both a tumor suppressor and promoter depending on the context, influenced by its interactions with the MEK-ERK signaling pathway.
Supporting Evidence
- PPARγ can be activated by both synthetic and natural ligands.
- PPARγ ligands have been shown to have both anti-tumor and pro-tumor effects.
- Interactions between PPARγ and MEK-ERK signaling can influence cancer cell behavior.
Takeaway
PPARγ is like a switch that can help or hurt cancer growth, depending on how it talks to other proteins in the cell.
Methodology
The review discusses various studies and mechanisms of action regarding PPARγ and MEK interactions in cancer.
Potential Biases
Potential bias in interpreting the dual roles of PPARγ due to varying contexts in different studies.
Limitations
The review is based on existing literature and does not present new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website